Add To My Watchlist
View My Watchlist

Green Zone Power Rating: 42 Neutral

Action to take: WATCH
Neutral stocks are expected to perform in line with the market over the next 12 months.
42
Price Based
Momentum
34
Size
65
Volatility
26
Fundamental Based
Value
55
Quality
50
Growth
49
Collapse Detail
NASDAQ%3ADVAX charts & data provided by TradingView

Latest Insights on DVAX

biopharma stock DVAX “Strong Bullish” Biopharma Stock Rips 130% Higher — and It’s Not Done
by Matthew Clark August 16, 2022 Investing
DVAX is a biopharma stock with promise as the company develops its signature hepatitis B vaccine. Here's why it's a buy today.